- Home
- PROV vs AVTX Comparison
PROV vs AVTX Comparison
Compare PROV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROV
- AVTX
- Stock Information
- Founded
- PROV 1956
- AVTX 2011
- Country
- PROV United States
- AVTX United States
- Employees
- PROV N/A
- AVTX N/A
- Industry
- PROV Savings Institutions
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PROV Finance
- AVTX Health Care
- Exchange
- PROV Nasdaq
- AVTX Nasdaq
- Market Cap
- PROV 107.5M
- AVTX 88.4M
- IPO Year
- PROV 1996
- AVTX 2015
- Fundamental
- Price
- PROV $14.26
- AVTX $7.70
- Analyst Decision
- PROV Hold
- AVTX Strong Buy
- Analyst Count
- PROV 1
- AVTX 5
- Target Price
- PROV $16.00
- AVTX $36.75
- AVG Volume (30 Days)
- PROV 5.6K
- AVTX 103.3K
- Earning Date
- PROV 04-28-2025
- AVTX 03-28-2025
- Dividend Yield
- PROV 3.93%
- AVTX N/A
- EPS Growth
- PROV N/A
- AVTX N/A
- EPS
- PROV 0.91
- AVTX N/A
- Revenue
- PROV $38,443,000.00
- AVTX $820,000.00
- Revenue This Year
- PROV $2.30
- AVTX N/A
- Revenue Next Year
- PROV $9.89
- AVTX N/A
- P/E Ratio
- PROV $15.67
- AVTX N/A
- Revenue Growth
- PROV N/A
- AVTX N/A
- 52 Week Low
- PROV $12.01
- AVTX $4.35
- 52 Week High
- PROV $16.70
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- PROV 25.11
- AVTX 51.98
- Support Level
- PROV $12.98
- AVTX $6.38
- Resistance Level
- PROV $14.85
- AVTX $8.40
- Average True Range (ATR)
- PROV 0.42
- AVTX 1.15
- MACD
- PROV -0.12
- AVTX 0.09
- Stochastic Oscillator
- PROV 43.84
- AVTX 27.66
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).